Who Paid My Doc
Christina Mingora
Internal Medicine Charleston, SC Medical Doctor
NPI 1114313335 CMS profile 7576997
171 Ashley Ave, Ste 816, Charleston, SC 29425
General payments
$1,031
Research payments
$1,395
Ownership & investment interest
$0
Through program year 2025, Christina Mingora of Charleston, SC is reported in the CMS Open Payments database as having received $1,031 across 8 general payments and $1,395 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 81st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $122 | 1 | |
| 2025 | Research | $1,395 | 11 | |
| 2024 | General | $398 | 1 | |
| 2023 | General | $144 | 1 | |
| 2022 | General | $171 | 2 | |
| 2021 | General | $46 | 2 | |
| 2020 | General | $150 | 1 |
Beside peers
- Christina Mingora
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Christina Mingora were reported at $122. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Christina Mingora | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $159 | $48–$570 | $163 |
| 2020 | $150 | $119 | $33–$402 | $114 |
| 2021 | $46 | $135 | $37–$521 | $132 |
| 2022 | $171 | $141 | $42–$496 | $149 |
| 2023 | $144 | $149 | $45–$519 | $160 |
| 2024 | $398 | $154 | $47–$537 | $164 |
| 2025 | $122 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 28 drugsPart D claims
975
Drug cost
$4,029,226
Branded share of claims
52.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trikafta Elexacaftor/Tezacaftor/Ivacaft | Brand | 88 | $2,226,622 | |
| Nuzyra Omadacycline Tosylate | Brand | 67 | $784,872 | |
| Arikayce Amikacin Liposomal/Neb.Accessr | Brand | 43 | $593,186 | |
| Creon Lipase/Protease/Amylase | Brand | 29 | $209,347 | |
| Dupixent Pen Dupilumab | Brand | 24 | $108,419 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 34 | $38,619 | |
| Voriconazole | Generic | 13 | $12,610 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 21 | $9,873 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 28 | $7,964 | |
| Imipenem-Cilastatin Sodium Imipenem/Cilastatin Sodium | Brand | 30 | $6,733 |
The 10 drugs with the highest cost, of 28 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$44,219
Medicare patients
437
Services billed
915
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| COPD | 65% | |
| Arthritis | 53% | |
| Osteoporosis | 32% | |
| Ischemic heart disease | 29% | |
| Diabetes | 28% | |
| Chronic kidney disease | 27% | |
| Depression | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in South Carolina
Related records
Internal Medicine in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.